Clin2
NCT05227326Possibly a fitRecruiting

A new drug for solid cancers that did not respond to usual care

Refractory Malignant Solid NeoplasmOsteosarcomaLeiomyosarcomasSynovial SarcomasOvarian CancerNon-Small Cell Lung CancerPancreatic Cancer

Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.

This early-stage (Phase 1) trial tests AOH1996 in adults with solid tumors that have stopped responding to standard treatments. It’s meant to find a safe dose and see if the drug can help, especially in cancers with limited options.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
92 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Be at least 18 years old
  • Have a solid tumor cancer that is not responding to usual treatments (or you refuse them)
  • Be able to do study visits/activities with an ECOG score of 2 or less (how well you function day to day)
  • Expect to live more than 3 months
  • Have acceptable blood test results (white blood cell type called ANC, platelets, liver and kidney tests) within 14 days before Day 1
  • Agree to birth control rules during the study and for 30 days after the last dose (if you could become pregnant)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06394492Recruiting· Phase 3
Testing a new drug for platinum-resistant ovarian cancer

This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.

Beijing, Beijing Municipality
NCT06840886Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This study tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can help shrink tumors.

Beverly Hills, California
NCT06652529Not yet recruiting· Phase 1
Testing a new drug AROG4-01 for advanced solid tumors

This trial tests a new drug called AROG4-01 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to find the right dose and see if the drug can help shrink or slow tumor growth.

NCT04999761Recruiting· Phase 1
Study testing new drug combinations for advanced cancers

This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.

Aichi
NCT07038343Recruiting· Phase 1/Phase 2
Testing a new drug for advanced solid tumors

This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.

Gilbert, Arizona
NCT06234098Recruiting· Phase 1/Phase 2
Study of a new drug for advanced solid tumors

This trial tests a new drug called AT-1965 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can shrink tumors.

Scottsdale, Arizona

Hear when a new Refractory Malignant Solid Neoplasm trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.